Recent Posts
- HealthInvest June 2026: A Look Inside Australia's Healthcare Innovations16 Jun 2026
- HealthInvest Returns for 2026: Meet the Companies Shaping Australian Life Sciences19 May 2026
- Lifesaving Capital: How impact investing is shaping the future of biotech30 Apr 2026
- Investor Relations: the quiet advantage powering ASX microcaps28 Nov 2025
- HealthInvest Sydney: Life Sciences in the Investor Spotlight06 Oct 2025
Archives

31 Aug 2022 · Cherie Hartley
IR Department client media highlights
IR Department client media highlights:
Read article
31 Aug 2022 · Paul Langley
Interview with Peter Devine, CEO of Uniseed
We talk with Peter Devine, CEO of Uniseed, about the current ESG landscape, ethical investing, their recent partnership with UniSuper and his surprising leisure activity.
Read article
29 Aug 2022 · Paul Langley
XPON CEO Matt Forman discusses Wondaris and how it integrates with Google
XPON's Founder and Group CEO Matt Forman explains the ground-breaking technology behind Wondaris and how it is changing the landscape of digital data recording.
Read article
29 Aug 2022 · Paul Langley
Race Oncology CSO Dr Daniel Tillett discusses the bright future for Zantrene
We speak with Dr Daniel Tillett, Chief Scientific Officer of Race Oncology, about the potential market and efficacy of their drug, Zantrene, which seems likely to change the cancer treatment landscape...
Read article
29 Aug 2022 · Paul Langley
Mosquito-borne diseases in Australia - an interview with Dr David Foster, CEO of Island Pharmaceuticals
We speak with Dr David Foster, CEO & Managing Director of Island Pharmaceuticals, about the current mosquito-borne diseases landscape in Australia. With recent outbreaks of dengue fever and Japane...
Read article
29 Aug 2022 · Paul Langley
Kazia Therapeutics CEO Dr James Garner talks with SmallCaps about what's on the horizon
Kazia Therapeutics (ASX: KZA) CEO James Garner joins Small Caps to discuss the company’s ongoing development of its lead drug paxalisib, which recently generated positive interim data in a phase one…
Read article
29 Aug 2022 · Paul Langley
Interview with Assoc.Prof. Mathias Francois of Gertrude Biomedical
We talk to Associate Professor Mathias Francois of Gertrude Biomedical, world-leaders in small molecular inhibitors to SOX18, a unique drug target with significant commercial and clinical potential
Read article
29 Aug 2022 · Paul Langley
HaemaLogiX's Tertia Dex explains the KappaMab antibody
HaemaLogix's Chief Manufacturing and Development Officer, Tertia Dex, explains the fascinating process to manufacture KappaMab, a highly-targeted antibody designed to treat mutliple myeloma.
Read article
04 Jul 2022 · Cherie Hartley
Podcast - IR Department talks with AdAlta CEO & MD, Dr Tim Oldham
Interview with AdAlta’s CEO & Managing Director Dr Tim Oldham
Read article